JP2014507412A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014507412A5 JP2014507412A5 JP2013549503A JP2013549503A JP2014507412A5 JP 2014507412 A5 JP2014507412 A5 JP 2014507412A5 JP 2013549503 A JP2013549503 A JP 2013549503A JP 2013549503 A JP2013549503 A JP 2013549503A JP 2014507412 A5 JP2014507412 A5 JP 2014507412A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination
- chloro
- methyl
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 10
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 9
- 229960001467 bortezomib Drugs 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- YFQJOPFTGMHYNV-YDALLXLXSA-N n-[(2s)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)thiophene-2-carboxamide;hydrochloride Chemical compound Cl.CN1N=CC(Cl)=C1C1=C(Cl)SC(C(=O)N[C@H](CN)CC=2C=C(F)C=CC=2)=C1 YFQJOPFTGMHYNV-YDALLXLXSA-N 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 4
- -1 4-chloro-1-methyl-1H-pyrazol-5-yl Chemical group 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 3
- 208000034578 Multiple myelomas Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- AFJRDFWMXUECEW-LBPRGKRZSA-N N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methyl-3-pyrazolyl)-2-thiophenecarboxamide Chemical compound CN1N=CC(Cl)=C1C1=C(Cl)SC(C(=O)N[C@H](CN)CC=2C=C(F)C=CC=2)=C1 AFJRDFWMXUECEW-LBPRGKRZSA-N 0.000 claims 2
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000003207 proteasome inhibitor Substances 0.000 claims 2
- BEBHRWCMWLGUCJ-UHFFFAOYSA-N thiophene-2-carboxamide;hydrochloride Chemical compound Cl.NC(=O)C1=CC=CS1 BEBHRWCMWLGUCJ-UHFFFAOYSA-N 0.000 claims 2
- YNSCKPCDFIDINW-UHFFFAOYSA-N 3-[[2-[[1-[2-(dimethylamino)acetyl]-6-methoxy-4,4-dimethyl-2,3-dihydroquinolin-7-yl]amino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]amino]thiophene-2-carboxamide Chemical compound COC1=CC(C(CCN2C(=O)CN(C)C)(C)C)=C2C=C1NC(N=C1NC=CC1=1)=NC=1NC=1C=CSC=1C(N)=O YNSCKPCDFIDINW-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000012609 Cowden disease Diseases 0.000 claims 1
- 201000002847 Cowden syndrome Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 1
- 208000036566 Erythroleukaemia Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims 1
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000000389 T-cell leukemia Diseases 0.000 claims 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 1
- 208000037833 acute lymphoblastic T-cell leukemia Diseases 0.000 claims 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 claims 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 201000011143 bone giant cell tumor Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161431508P | 2011-01-11 | 2011-01-11 | |
| US61/431,508 | 2011-01-11 | ||
| PCT/US2012/020863 WO2012097021A1 (en) | 2011-01-11 | 2012-01-11 | Combination |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014507412A JP2014507412A (ja) | 2014-03-27 |
| JP2014507412A5 true JP2014507412A5 (enExample) | 2015-03-05 |
| JP6100700B2 JP6100700B2 (ja) | 2017-03-22 |
Family
ID=46507420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013549503A Active JP6100700B2 (ja) | 2011-01-11 | 2012-01-11 | 組合せ |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US20130288984A1 (enExample) |
| EP (1) | EP2663189B1 (enExample) |
| JP (1) | JP6100700B2 (enExample) |
| KR (1) | KR20140053836A (enExample) |
| CN (1) | CN103298345B (enExample) |
| AU (1) | AU2012205601B2 (enExample) |
| BR (1) | BR112013017722A2 (enExample) |
| CA (1) | CA2824201A1 (enExample) |
| EA (1) | EA029000B1 (enExample) |
| ES (1) | ES2689760T3 (enExample) |
| IL (1) | IL227097B (enExample) |
| MX (1) | MX356704B (enExample) |
| SG (2) | SG10201600077RA (enExample) |
| WO (1) | WO2012097021A1 (enExample) |
| ZA (1) | ZA201304139B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109806266A (zh) * | 2013-10-01 | 2019-05-28 | 诺华股份有限公司 | 用于癌症治疗的组合及其应用 |
| JP6568093B2 (ja) * | 2013-11-07 | 2019-08-28 | デシフェラ ファーマシューティカルズ，エルエルシー | ガンの処置に有用なｔｉｅ２キナーゼの阻害方法 |
| IL276398B2 (en) | 2018-01-31 | 2026-03-01 | Deciphera Pharmaceuticals Llc | Combination therapy for mastocytosis |
| CN118416236A (zh) | 2018-01-31 | 2024-08-02 | 德西费拉制药有限责任公司 | 治疗胃肠道间质瘤的组合疗法 |
| WO2020185812A1 (en) | 2019-03-11 | 2020-09-17 | Teva Pharmaceuticals International Gmbh | Solid state forms of ripretinib |
| EP4013412B1 (en) | 2019-08-12 | 2026-01-28 | Deciphera Pharmaceuticals, LLC | Ripretinib for treating gastrointestinal stromal tumors |
| TWI878335B (zh) | 2019-08-12 | 2025-04-01 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| EP4084779B1 (en) | 2019-12-30 | 2024-10-09 | Deciphera Pharmaceuticals, LLC | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| MX2022008103A (es) | 2019-12-30 | 2022-09-19 | Deciphera Pharmaceuticals Llc | Formulaciones de inhibidores de la cinasa amorfa y metodos de estas. |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6328590B1 (en) | 2000-07-20 | 2001-12-11 | Emc Corporation | Methods and apparatus for controlling attachment of an electronic module with a circuit board connector |
| EP1740579B1 (en) * | 2004-03-24 | 2015-08-19 | AbbVie Inc. | Tricyclic pyrazole kinase inhibitors |
| KR100872675B1 (ko) | 2004-10-13 | 2008-12-10 | 파마시아 앤드 업존 캄파니 엘엘씨 | 3-[5-클로로-4-[(2,4-디플루오로벤질)옥시]-6-옥소피리미딘-1(6ｈ)-일]-ｎ-(2-히드록시에틸)-4-메틸벤즈아미드의결정형 |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| EP2275095A3 (en) * | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP1840114A1 (en) | 2006-03-30 | 2007-10-03 | LTB4 Sweden AB | Crystalline Leukotriene B4 |
| KR20080108516A (ko) | 2006-04-05 | 2008-12-15 | 노파르티스 아게 | 암을 치료하기 위한 치료제의 조합물 |
| WO2007122686A1 (ja) | 2006-04-14 | 2007-11-01 | Eisai R & D Management Co., Ltd. | ベンズイミダゾール化合物 |
| PL2478907T3 (pl) | 2006-08-25 | 2021-10-25 | Janssen Oncology, Inc. | Kompozycje do leczenia nowotworu |
| US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| JP4299327B2 (ja) | 2006-08-31 | 2009-07-22 | トヨタ自動車株式会社 | 可変バルブタイミング装置 |
| US8828451B2 (en) * | 2006-10-04 | 2014-09-09 | University Of South Florida | Akt sensitization of cancer cells |
| CL2007002948A1 (es) | 2006-10-13 | 2008-05-30 | Basf Ag | Hidratos del compuesto 2-cloro-5-(3,6-dihidro-3-metil-2,6-dioxo-4-(trifluorometil)-1-(2h)-pirimidinil)-4-fluor-n-((metil(1-metiletil)amino)sulfonil]benzamida; proceso para la preparacion de dicho hidrato; composicion fitoprotectora; y metodo para con |
| AR064010A1 (es) | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| PL2201012T3 (pl) | 2007-10-11 | 2014-11-28 | Astrazeneca Ab | Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b |
| US20090131367A1 (en) * | 2007-11-19 | 2009-05-21 | The Regents Of The University Of Colorado | Combinations of HDAC Inhibitors and Proteasome Inhibitors |
| DE102008044901A1 (de) | 2008-08-29 | 2010-03-04 | Siemens Aktiengesellschaft | Verfahren und Vorrichtung zur Auswahl eines Bestrahlungsplans sowie Bestrahlungsanlage |
| CN102405047B (zh) | 2009-01-30 | 2014-07-09 | 葛兰素史密斯克莱有限责任公司 | 结晶型的n-{(1s)-2-氨基-1-[(3-氟苯基)甲基]乙基}-5-氯-4-(4-氯-1-甲基-1h-吡唑-5-基)-2-噻吩甲酰胺盐酸盐 |
| WO2010149755A1 (en) | 2009-06-26 | 2010-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
| MX2012004140A (es) | 2009-10-08 | 2012-09-07 | Glaxosmithkline Llc | Combinacion. |
| WO2012135781A1 (en) | 2011-04-01 | 2012-10-04 | Genentech, Inc. | Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use |
| AU2012250650A1 (en) | 2011-05-03 | 2013-11-14 | University Of Rochester | Methods for treating prostate cancer |
| JP2014520863A (ja) | 2011-07-13 | 2014-08-25 | ファーマサイクリックス，インク． | Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤 |
| CN104066744B (zh) | 2011-10-10 | 2017-03-22 | 扎克系统公司 | 用于制备17‑取代的甾体的方法 |
| HRP20191982T4 (hr) | 2011-11-30 | 2023-01-06 | Astrazeneca Ab | Kombinacijsko liječenje raka |
| KR20210033067A (ko) | 2012-06-04 | 2021-03-25 | 파마싸이클릭스 엘엘씨 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
| MX2016004265A (es) | 2013-10-01 | 2016-07-08 | Novartis Ag | Combinacion. |
-
2012
- 2012-01-11 SG SG10201600077RA patent/SG10201600077RA/en unknown
- 2012-01-11 CN CN201280004830.0A patent/CN103298345B/zh active Active
- 2012-01-11 US US13/978,765 patent/US20130288984A1/en not_active Abandoned
- 2012-01-11 SG SG2013043856A patent/SG191724A1/en unknown
- 2012-01-11 MX MX2013008074A patent/MX356704B/es active IP Right Grant
- 2012-01-11 EP EP12733916.6A patent/EP2663189B1/en active Active
- 2012-01-11 ES ES12733916.6T patent/ES2689760T3/es active Active
- 2012-01-11 WO PCT/US2012/020863 patent/WO2012097021A1/en not_active Ceased
- 2012-01-11 BR BR112013017722A patent/BR112013017722A2/pt not_active IP Right Cessation
- 2012-01-11 KR KR1020137021098A patent/KR20140053836A/ko not_active Abandoned
- 2012-01-11 AU AU2012205601A patent/AU2012205601B2/en not_active Ceased
- 2012-01-11 CA CA2824201A patent/CA2824201A1/en not_active Abandoned
- 2012-01-11 JP JP2013549503A patent/JP6100700B2/ja active Active
- 2012-01-11 EA EA201391027A patent/EA029000B1/ru not_active IP Right Cessation
- 2012-02-08 US US13/368,434 patent/US20120258933A1/en not_active Abandoned
-
2013
- 2013-06-06 ZA ZA2013/04139A patent/ZA201304139B/en unknown
- 2013-06-20 IL IL227097A patent/IL227097B/en active IP Right Grant
-
2015
- 2015-01-06 US US14/590,143 patent/US20150119337A1/en not_active Abandoned
- 2015-08-20 US US14/831,261 patent/US20160022641A1/en not_active Abandoned
-
2016
- 2016-09-08 US US15/259,694 patent/US20160375086A1/en not_active Abandoned
- 2016-12-20 US US15/385,205 patent/US10449226B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014507412A5 (enExample) | ||
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| RU2015154275A (ru) | Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf | |
| JP2014511840A5 (enExample) | ||
| JP2019510832A5 (enExample) | ||
| JP2016503399A5 (enExample) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2012255026A5 (enExample) | ||
| JP2013509429A5 (enExample) | ||
| RU2014141362A (ru) | Комбинированная терапия пролиферативных нарушений | |
| JP2018168191A5 (enExample) | ||
| JP2015511609A5 (enExample) | ||
| RU2015119218A (ru) | Комбинация | |
| JP2013518107A5 (enExample) | ||
| JP2017511360A5 (enExample) | ||
| JP2014510729A5 (enExample) | ||
| FI3429571T3 (fi) | Lsd1-inhibiittorien yhdistelmiä käytettäväksi kasvaintautien hoitamisessa | |
| HRP20191617T1 (hr) | Kombinacija koja sadrži inhibitor mek i inhibitor b-raf | |
| JP2010528026A5 (enExample) | ||
| HRP20120918T1 (hr) | Aminopirazolski spoj | |
| RU2017102319A (ru) | Прерывистое введение ингибитора mdm2 | |
| JP2012516344A5 (enExample) | ||
| RU2015121424A (ru) | Комбинированная терапия | |
| HRP20150530T1 (hr) | Spojevi korisni za inhibiranje chk1 | |
| JP2011520846A5 (enExample) |